Long-term treatment of girls with ornithine transcarbamylase deficiency
- PMID: 8778603
- DOI: 10.1056/NEJM199609193351204
Long-term treatment of girls with ornithine transcarbamylase deficiency
Abstract
Background: Ornithine transcarbamylase is an X-linked mitochondrial enzyme that catalyzes the synthesis of citrulline from carbamoyl phosphate and ornithine. A deficiency of this enzyme leads to hyperammonemia and hyperglutaminemia. In boys the disease is often fatal when its onset occurs during the neonatal period, but it is milder when onset occurs later in childhood. Heterozygous girls may be normal or may have episodes of hyperammonemic encephalopathy and decline in cognitive function. We report here on the long-term outcome in girls with ornithine transcarbamylase deficiency enrolled in studies of treatments designed to activate new pathways of waste-nitrogen excretion.
Methods: We studied 32 girls (age, 1 to 17 years) with ornithine transcarbamylase deficiency who had had at least one episode of encephalopathy. The patients were assigned to treatment that consisted of sodium benzoate, alone or in combination with sodium phenylacetate or sodium phenylbutyrate, or sodium phenylbutyrate alone. Collaborating physicians provided clinical, metabolic, and developmental data at specified intervals.
Results: Patients treated according to these protocols had greater than 90 percent survival at five years and maintained appropriate weight for height. The frequency of hyperammonemic episodes decreased with increasing age and with sodium phenylacetate or sodium phenylbutyrate treatment. Although the mean IQ before treatment was in the low average range, 19 of the 23 girls in whom intelligence was tested longitudinally had stable test scores.
Conclusions: Girls with symptomatic ornithine transcarbamylase deficiency who are treated with drugs that activate new pathways of waste-nitrogen excretion have fewer hyperammonemic episodes and a reduced risk of further cognitive decline.
Similar articles
-
Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.N Engl J Med. 2007 May 31;356(22):2282-92. doi: 10.1056/NEJMoa066596. N Engl J Med. 2007. PMID: 17538087 Clinical Trial.
-
Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients.Mol Genet Metab. 2001 Apr;72(4):351-5. doi: 10.1006/mgme.2001.3156. Mol Genet Metab. 2001. PMID: 11286510
-
Treatment of urea cycle disorders.J Pediatr. 1999 Mar;134(3):255-6. doi: 10.1016/s0022-3476(99)70443-9. J Pediatr. 1999. PMID: 10064655 Review. No abstract available.
-
The role of orthotopic liver transplantation in the treatment of ornithine transcarbamylase deficiency.Liver Transpl Surg. 1998 Sep;4(5):350-4. doi: 10.1002/lt.500040504. Liver Transpl Surg. 1998. PMID: 9724471 Review.
-
Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the ornithine transcarbamylase-deficient sparse-fur mouse.Pediatr Res. 1988 Apr;23(4):368-74. doi: 10.1203/00006450-198804000-00006. Pediatr Res. 1988. PMID: 3374991
Cited by
-
Comprehensive molecular and cellular characterization of endoplasmic reticulum stress-related key genes in renal ischemia/reperfusion injury.Front Immunol. 2024 Mar 1;15:1340997. doi: 10.3389/fimmu.2024.1340997. eCollection 2024. Front Immunol. 2024. PMID: 38495888 Free PMC article.
-
Father-to-daughter transmission in late-onset OTC deficiency: an underestimated mechanism of inheritance of an X-linked disease.Orphanet J Rare Dis. 2024 Jan 2;19(1):3. doi: 10.1186/s13023-023-02997-8. Orphanet J Rare Dis. 2024. PMID: 38167094 Free PMC article.
-
Induced pluripotent stem cell technology as diagnostic tool in patients with suspected ornithine transcarbamylase deficiency lacking genetic confirmation.Mol Genet Metab Rep. 2023 Sep 6;37:101007. doi: 10.1016/j.ymgmr.2023.101007. eCollection 2023 Dec. Mol Genet Metab Rep. 2023. PMID: 38053928 Free PMC article.
-
Genetic disorders of neurotransmitter release machinery.Front Synaptic Neurosci. 2023 Mar 31;15:1148957. doi: 10.3389/fnsyn.2023.1148957. eCollection 2023. Front Synaptic Neurosci. 2023. PMID: 37066095 Free PMC article. Review.
-
4-Phenylbutyrate Mitigates the Motor Impairment and Dopaminergic Neuronal Death During Parkinson's Disease Pathology via Targeting VDAC1 Mediated Mitochondrial Function and Astrocytes Activation.Neurochem Res. 2022 Nov;47(11):3385-3401. doi: 10.1007/s11064-022-03691-0. Epub 2022 Aug 3. Neurochem Res. 2022. PMID: 35922743
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical